Eric A. Schon, Giovanni Manfredi
Submitter: Sergio Stagnaro | firstname.lastname@example.org
Via Erasmo Piaggio 23/8 16037 Riva Trigoso (Genoa) Italy
Published February 10, 2003
Sirs, in the war against the most common human diseases, including cancers, we must especially to study a clinical tool that helps “all” doctors in bed side recognizing, in apparently healthy individuals, genetical errors, e.g., hyperinsulinemia-insulinresistance, melatonine deficiency, metabolic disorders, prevalence of stress axis, a.s.o., which either bring about or aggravate chromosomal aberrations as those observed in cancer cells. In fact, our target can be reached hopefully if “all” doctors are able to ascertain or at least suspect at the bed-side in apparently health persons chromosomal aberrations, before cancer on-set. As a working hypothesis, I thought previously that all chromosomal alterations, both nuclear and mithocondrial, of whatever nature, are necessarily accompanied with similar microvascular modification of the local microcirculatory bed, both structural and functional in nature, in subject involved by abnormalities of pschyco-neuro-endocrinological-immune system (See:Oncological Terrainin my site, HONCode ID, N. 233736, http://digilander.libero.it/semeioticabiofisica). As a matter of fact, both genetical and environmental factors induce contemporaneously parenchymal and microvascular cells alterations, according to the well- known Tiscedorf’s “Angiobiotopie”. For instance, a family of molecules called cyclins was descovered. It is through changes in the production of cyclins during the cell cycle that the activity of the genes controlling it are themselves regulated. All these events (control, regulation a.s.o.), however, can happen only by means of changes in local microcirculation, i.e., in information-material-energy supply to tissue. Now, fortunately, thanks to Biophysical Semeiotics (See the above cited-site), we can evaluate clinically microcirculatory bed structure and function in a precise manner (2-5). Based on 45-year-long "clinical" experience, the decline in cancer rates all over the world could be more intense if scientists will think over and discuss the possibility that exists the "Oncological Terrain". As a matter of fact, e.g., not all smokers are involved by pulmonary cancer, as well as not all people with chronic hepatitis will die of hepatocarcinoma. On the other side, in some families malignancies occur more frequently than in others. Actually, as I described in the above-mentioned papers, there are other causes that accounts for the reason of existence of the oncological “real” risk, i.e. oncological terrain, which is based upon a particular form of mitochondrial cytopathology (See above cited site: Congenital Acidosic Enzyme-Metabolic Histangiopathy). At this point, the first question is the following: "What does characterize oncological terrain from the "clinical" point of view?". In fact, in order to achieve efficacious cancer prevention on very large scale it is unavoidable that the modifications occurring in the biological controll system could be easily, promptly, and “quantitatively” ascertained and properly evaluated with the aid of a “clinical” method, i.e. by the use of a sthetoscope, and certainly without application of sophysticated semeiotics, that does not apply in all individuals, on a very large scale, and, moreover, only a few doctors can utilize them. If it is possible to answer this first question, a second one immediately follows: "The oncological terrain which certanly can be induced, is also in some way reversible?" It is urgent and necessary to know if the oncological terrain can be reversed, i.e. if it can totally or greatly disappeare, with the aid of drugs or diet, ethymologically speaking, which exert a favourable influence on the characteristic modifications of the psicho-neuro-endocrine- immunological system, that represent “oncological terrain”. My answers to these questions are readable in my site (5). The war against cancer will be fortunately won if all doctor are going to recognize, with the aid of a stethoscope, individual apparently health but positive for “oncological terrain”, particularly intense in a well defined tissue region, who have to undergo immediately to proper diet, ethymologically speaking, and drugs, in some cases. Unfortunately, change in Medicine is an up-hill task and most doctors ignore both physiology and pathology of mitochondria ! Moreover, in the discussion between theories the power of the antagonists is more important than that of the ideas. But, fortunately, ideas go on and on, and on..., although slowly. Hopenly, somebody will spread this interesting knowledge about "oncological terrain", as I recently did also in the page, I hold weekly, on the italian site www.katamed.it. , article N° 13, as well as on www.staibene.it.
Stagnaro Sergio MD., Member NYAS Riva Trigoso (Genoa) Italy.
1) Watts G. Three cell cycle scientists win Nobel prize. BMJ 2001; 323:823 (13 October).
2) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica del torace, della circolazione ematica e dell’anticorpopoiesi acuta e cronica. Acta Med. Medit. 13, 25 1997
3) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica: la manovra di Ferrero-Marigo nella diagnosi clinica della iperinsulinemia-insulino resistenza. Acta Med. Medit. 13, 125 1997.
4) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica: valutazione clinica del picco precoce della secrezione insulinica di base e dopo stimolazione tiroidea, surrenalica, con glucagone endogeno e dopo attivazione del sistema renina-angiotesina circolante e tessutale – Acta Med. Medit. 13, 99.
5) Stagnaro S., Sindrome percusso-ascoltatoria di Iperfunzione del Sistema Reticolo-Istiocitario. Min. Med. 74, 479, 1983 (Pub-Med indexed for Medline)